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TBVAC2020 is a research project supported by the Horizon 2020 program of the 
European Commission (EC). It aims at the discovery and development of novel tuber-
culosis (TB) vaccines from preclinical research projects to early clinical assessment. The 
project builds on previous collaborations from 1998 onwards funded through the EC 
framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners 
from outstanding laboratories from all over the world, now totaling 40 institutions. Next 
to the development of novel vaccines, TB biomarker development is also considered 
an important asset to facilitate rational vaccine selection and development. In addition, 
TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, 
and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 
consortium coordinated by TBVI facilitates collaboration and early data sharing between 
partners with the common aim of working toward the development of an effective TB 
vaccine. Close links with funders and other consortia with shared interests further con-
tribute to this goal.
Keywords: tuberculosis, bacille Calmette–Guérin, vaccination, biomarker, clinical trial, portfolio management, 
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iNTRODUCTiON
One hundred years ago, Albert Calmette (1863–1933) and Camille Guérin (1872–1961) had almost 
reached their goal (1). They had passaged Mycobacterium bovis 200 times at 14 d intervals on potato 
slices soaked with ox gall in their attempt to generate an attenuated vaccine against tuberculosis 
(TB). They had started their program in 1906 and had already obtained preliminary evidence for 
safety and protection of their candidate in 1913. Yet, they continued until they had completed the 
230th passage before verifying its efficacy and safety in experimental animals including guinea pigs, 
rabbits and non-human primates (NHPs) as well as in the natural host, cattle. The data obtained 
were highly promising so Calmette and Guérin started the first vaccination of a human neonate born 
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into a household with a TB patient. Risk of TB in a household-
contact infant at those times was extremely high. Yet, the baby 
did not develop TB and after additional encouraging results, 
vaccinations of more than 20,000 neonates in households with 
at least one TB patient were performed between 1921 and 1924. 
The results of this trial revealed that of the vaccinees 5% had died 
and 1% of these of TB, whereas knowledge of the time held that a 
quarter of non-vaccinated newborns would die in the first years 
of life, many of them of TB (1). This is the start of Bacille Bilié 
Calmette-Guérin, later shortened to Bacille Calmette–Guérin 
(BCG), which remains the only licensed vaccine against TB until 
today. Although not perfect, this vaccine partially fulfills the 
goal set by Calmette and Guérin, since it protects against extra-
pulmonary forms of disease in infants, including life threatening 
TB meningitis. Unfortunately, in most settings, BCG does not 
reliably prevent pulmonary TB, the most prevalent and the most 
contagious form in all age groups from the neonatal to the elderly 
population. The lack of an efficient vaccine against pulmonary 
TB is a major obstacle to control TB satisfactorily until today.
In 1993, the World Health Organization (WHO) declared TB 
a global emergency at a time when some 4–6 million new TB 
cases per year were notified. With the introduction of a new treat-
ment regimen, called directly observed treatment, short-course 
(DOTS) program, WHO claimed to bring TB under control and 
predicted a decline from 6–8 million new cases in 1997 to 2–3 
million new cases by 2017 by implementing highly intensive 
DOTS (2). Unfortunately, this hope failed miserably. The most 
recent notifications reveal a stunning 10.4 million new cases and 
1.8 million deaths in 2015. Building on better drug regimens 
alone not only proved to be insufficient in controlling TB, it also 
led to increasing incidences of multi-drug-resistant forms of TB.
At this time, researchers interested in the mechanisms under-
lying immunopathology and immune protection of TB were 
concerned that the efficacy of DOTs might be overestimated 
and considered a better TB vaccine a necessity for efficient TB 
control. Thus, a proposal on TB vaccines was submitted to the 
European Commission (EC) funded framework program (FP) 5 
and this was funded from 1998 to 2002. The subsequent FP 6 and 
FP 7 programs continued to support TB vaccine-related research 
until 2013. During this period, enormous progress was achieved, 
not only resulting in the development of a number of promising 
vaccine candidates but also providing deeper understanding of 
immune mechanisms underlying protection and pathology in 
TB as well as identifying new TB biomarkers (BMs). These FP5 
to FP7 activities were succeeded by the Horizon 2020 program 
which further supported TB vaccine research and development. 
It is this continuous support over the past 20  years which has 
welded together researchers from all over Europe and other parts 
of the globe to harness cutting-edge knowledge in the immunol-
ogy, microbiology, and high end technology platforms for the 
development of novel TB vaccine candidates. This sustained EC 
funding made it possible to establish a unique European consor-
tium responsible for most of the global innovation in TB research.
This EC-funded activity proved extremely successful. Over 
50% of the global pipeline in TB vaccine candidates currently 
evaluated in clinical trials originate from EC funded projects (3). 
The EC has played a key leadership role in accelerating TB vaccine 
research and development and ensured a well-coordinated and 
efficient TB vaccine research consortium.
At the same time, the pipeline needs to be fed constantly with 
new innovative candidates since it is unlikely that one single 
vaccine could protect against all different forms of TB disease in 
all age groups and for all indications. Thus, the concept of diver-
sification gained increasing importance. Different vaccine types 
(subunit vaccines vs. whole cell vaccines), different administra-
tion schedules (pre-exposure vs. post-exposure), different age 
groups (neonates vs. adults) and different purposes (prevention 
of infection vs. disease vs. recurrence of disease), and perhaps 
even therapeutic TB vaccines have all to be considered.
Already before the beginning of TBVAC2020, it was realized 
that an isolated vaccine development approach was inadequate 
and needed to be complemented by deeper knowledge of patho-
mechanisms, immunology, and microbiology; by established as 
well as novel animal models; by identifying biosignatures of TB 
disease, risk of disease, vaccine efficacy, and safety (3–6). Finally, 
with increasing numbers of vaccines being ready for clinical 
testing, early clinical trials needed to be integrated. Although 
TBVAC2020 and its predecessors respect individual researchers’ 
autonomy, it was deemed of increasing importance to also pro-
vide a portfolio management process, including consensus gating 
criteria, to objectively and transparently guide further product 
and clinical development of TB vaccine candidates (7). This arti-
cle describes the different activities of the Horizon 2020 funded 
TBVAC2020 project which is coordinated by TBVI summarizing 
recent achievements and future goals as part of the European 
effort to successfully combat TB. Figure 1 provides an overview 
of the close interactions between different WorkPackage (WP) 
activities and progression of promising vaccine candidates from 
discovery via preclinical testing to clinical trial. Although TBVI 
has coordinated much of the European research efforts on TB 
vaccine development to date, there are other ongoing activities, 
for example, through the Aeras Foundation1 and the EMI-TB 
Consortium.2
wP1 DiSCOveRY OF NOveL TB  
vACCiNe STRATeGieS
A major objective of TBVAC2020 is the identification of novel 
vaccine candidates for subsequent preclinical and early clinical 
development. To this end, the objective of WP1 is to develop 
innovative approaches and platforms for TB vaccination in 
three areas: (i) the discovery of novel antigens and live vaccines; 
(ii) the exploration and implementation of novel immunization 
strategies and vaccination platforms; and (iii) the optimization 
of formulation and delivery of available subunit and live vaccine 
candidates.
Antigen Discovery
The identification of novel antigens is the initial and critical step 
in developing new vaccination strategies. It is well established 
1 www.aeras.org.
2 www.emi-tb.org.
FiGURe 1 | Overview of the TBVAC2020 project structure indication interactions between WorkPackages (WPs) and flow from discovery via preclinical testing to 
clinical trial of most promising vaccine candidates.
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that polyfunctional effector T cell subsets act in concert to acti-
vate macrophages to limit mycobacterial replication and prevent 
progression of latent infection to active disease. Our key objective 
is, therefore, to identify antigens that trigger protective lympho-
cyte subsets and to improve their delivery to antigen-presenting 
cells. Specifically, this sub-work package aims to identify: (i) new 
immunogenic epitopes derived from Mycobacterium tuberculosis 
(Mtb)-infected macrophages; (ii) new immunogenic proteins 
and lipoproteins of Mtb; (iii) new immunogenic lipids of Mtb; 
and (iv) antigens that induce antibody-mediated protection.
A high level of innovation is being achieved by applying 
sophisticated techniques, e.g., for the elution of peptides from 
human leukocyte antigen (HLA)-molecules from Mtb-infected 
antigen-presenting cells using a data-independent acquisition 
(DIA) method which aims to complement traditional mass 
spectrometry-based proteomics techniques and SRM methods 
(SWATH-MS) (8). This unbiased approach allows the identi-
fication of immunogenic antigens that are presented during 
natural infection with Mtb. The use of transcriptomic analysis 
is another unbiased approach to identify antigens expressed at 
the site of infection. Unbiased transcriptomic approaches were 
also used to identify antigens expressed at the site of infection. 
A number of new in vivo expressed (IVE) Mtb antigens were 
identified that were highly expressed in the lungs of TB suscep-
tible (C3HeB/FeJ) mice. Using various predictive algorithms, 
including potential HLA-I and -II presented epitopes many new 
antigens were identified that activated both conventional and 
unconventional T-cells from latently infected individuals (9). 
Of note, many IVE-TB antigen-directed T  cell responses were 
characterized by the production of cytokines other than IFNγ. 
Studies are ongoing to dissect antibody recognition of this novel 
class of antigens.
In parallel to these unbiased approaches, WP1 is following 
hypothesis-driven approaches for the discovery of vaccine can-
didates. For example, stage-specific, subdominant mycobacterial 
antigens encoded by genes co-regulated with those encoding 
latency antigens, such as the heparin-binding hemagglutinin 
(HBHA) (10) are being evaluated. Recently, the importance 
of Mtb-specific chemokine receptor expression (CXCR3+ and 
CXCR5+) lung-homing T  lymphocytes in protection against 
TB has been demonstrated (11). This knowledge has been 
exploited to show that the liposome-adjuvanted fusion protein 
H56/CAF01 confers durable protection against TB by eliciting 
protective T-cells expressing CXCR3 in the lung, while limiting 
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the induction of non-protective intravascular T-cells (12). The 
identification and evaluation of lipid antigens is another key 
objective of WP1. Using protease cleavable CD1b-molecules, 
formulation of lipid-containing liposomes (13) or inclusion of 
α-galactosyl ceramide (α-GalCer) (14) to activate iNKT  cells 
the potential of lipid antigens as vaccines is being evaluated. 
Liposomes are a particularly attractive delivery system, because 
they offer a simple and flexible platform to combine antigens and 
adjuvants, including immune modulators triggering the toll-like 
receptor (TLR) pathways (15).
Another innovative concept addressed in WP1 is the hitherto 
almost completely neglected search for Mtb antigens that trigger 
protection-associated antibody responses (16). To address this 
issue, Mtb-specific antibodies are being isolated from patients 
and immunized mice, and their mycobacterial targets are being 
identified.
Delivery Systems and immunization 
Strategies
Mucosal Delivery
The induction of protective immune responses in the lung, which 
is the site of Mtb-entry, is elementary for vaccine development. 
Previous data showed that BCG vaccination via the pulmonary 
route confers superior protection when compared to the 
subcutaneous route, which relies at least in part on Th17 cells 
(17–19). Mimicking the natural route of infection, the protec-
tive efficacy of whole-cell live-attenuated Mtb ΔphoPΔfadD26 
(MTBVAC) delivered intranasally is being explored. A specific 
lung-targeted approach is to develop an inert pulmonary deliv-
ery platform, which can “pull” antigen-specific Th17 cells from 
the circulation into the lungs to form a depot of tissue-resident 
memory cells.
Designing Novel Adjuvants
Local pulmonary immunity could also be induced by parenteral 
delivery of adjuvants designed to promote site-specific homing of 
protective T cells. In this regard CD4+CXCR5+ T-cells promote 
early and efficient macrophage activation, and their recruitment 
requires a pre-existing Th17 response (20). This knowledge is 
translated into a new strategy by implementation of the Th17-
inducing adjuvant, CAF01, combined with stimulators of CXCR5, 
CXCR3, and CCR4 known to favor pulmonary homing.
Synthetic glycolipids also have potent adjuvant activity and 
homologs of various mycobacterial glycolipids induce the inflam-
masome and have adjuvant activity in  vivo (21). In particular, 
vaccination of mice with recombinant PPE44 formulated in 
dimethyldioctadecylammonium and synthetic glucose mono-
mycolate (GMM) induced protective immunity against Mtb, 
with comparable efficacy to BCG. Induction of CD1b-restricted 
GMM-specific responses by this formulation is currently being 
tested in guinea pigs.
Developing Novel Inert and Viral Vector-Based 
Delivery Systems
Pre-existing anti-Mtb antibodies in the lung mucosa have also 
been suggested as a strategy to prevent infection, but so far it 
has been difficult to induce high-titer and long-lived antibody 
responses against structural antigens. A novel nanoparticle-based 
technology is being exploited for the delivery of synthetic cell 
wall antigens, a technology that has shown excellent results in 
the field of influenza (22). Improved viral vectors are currently 
being evaluated in WP1, including non-integrative lentiviral 
vectors (LV), chimpanzee adenoviral (ChAd) vectors, lympho-
cytic choriomeningitis virus and influenza virus. In particular, 
a vaccine regime using two viral vectors has been optimized: a 
ChAd vector (ChAdOx1) and a modified vaccinia virus Ankara 
(MVA), both expressing Ag85A. A boost of BCG with intranasal 
(i.n.) ChAdOx1.85A followed by a second boost with i.n. or 
intradermal MVA85A, significantly improved BCG vaccination 
in mice (23).
Novel Live vaccines
Past research programs (TBVAC and NEWTBVAC) have suc-
ceeded in developing novel live vaccines, including BCGΔureC:hly 
(VPM1002) (24), MTBVAC (25, 26), which already progress 
through clinical trials, and BCGΔzmp1 which is considered 
for clinical testing in the near future. One of the aims of WP1 
is to build upon these first-generation live vaccines as well as to 
provide novel live vaccine candidates based on strong scientific 
rationale.
Mtb ΔphoPΔfadD26 will be used as a basis to search for safer 
and more effective mycobacteria-based vaccines to be used in 
immune-compromised individuals. Specifically, an additional 
virulence gene, erp, has been deleted from MTBVAC resulting in 
increased attenuation (27). To improve protection by MTBVAC, 
a genome-wide screening approach is being performed, in which 
random mutants are screened in mice for safety and protective 
efficacy. Deletion of the anti-apoptotic factor nuoG in VPM1002 
resulted in improved safety and protection as compared to BCG 
and VPM1002 in the mouse model (28). A safer VPM1002 
derivative was created by deletion of pdx1 rendering the vaccine 
auxotrophic for vitamin B6 (29). Finally, an attenuated Mtb ESX-5 
mutant, MtbΔppe25-pe19, is safe and more protective than BCG 
in mice (30). The mechanism of attenuation is yet unknown, but 
likely results from phagosomal-rupture-induced innate immune 
signaling.
To summarize, WP1 has identified promising novel adjuvants, 
delivery systems, and live vaccine candidates that are currently 
evaluated for safety, immunogenicity, and protective efficacy in 
appropriate animal models, in collaboration with partners in 
other WPs.
wP2 ANiMAL MODeL ReFiNeMeNT  
AND DeveLOPMeNT
In the absence of unambiguous markers that correlate with and, 
thus, predict vaccine-induced protective immunity against Mtb 
infection and TB disease (31, 32), experimental infection mod-
els remain an indispensable tool in the process of TB vaccine 
research and development. And while at present no animal-
free systems exist that fully recapitulate the complexity of host 
defense cascades and pathogenesis (33), it is imperative to exploit 
animals at various (staggered) stages of this vaccine Research and 
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Development (R&D) process and in particular to demonstrate 
vaccine efficacy (34).
Typically, several lower and also higher vertebrate animal spe-
cies are utilized as models from as early as discovery up to build-
ing qualification dossiers and down selecting the best candidate 
vaccines toward resource-consuming, advanced stage clinical 
testing (Phase II and later) (35). These models are not only used 
to investigate the protective efficacy against an infectious chal-
lenge but also to assess vaccine tolerability (or, in specific cases, 
attenuation of live vaccines as a parameter of vaccine safety) and 
immunogenicity of new approaches, which build upon or extend 
beyond the current BCG vaccine.
Strictly speaking, no single animal model has been validated 
for the ultimate predictive assessment of TB vaccines toward the 
various target populations that can be identified globally. Models 
by definition imply a simplification of real-life complexity. Espe-
cially in the light of developing new preventive/prophylactic 
vaccine strategies, we, therefore, explore candidate vaccine 
performance in several different models to strengthen its proof-
of-concept and to de-risk the development process for possible 
failures (35). In recognition of the undoubted limitations of any 
specific model, centralized and independent preclinical evalua-
tion modalities are established in mouse, guinea pig, and NHP 
hosts, as described in WP3.1.
Mostly, preclinical studies assess the prophylactic profile of 
vaccine candidates in healthy animal hosts, which are experimen-
tally challenged with Mtb and that are immunologically naive to 
mycobacterial antigens and typically free from any other disease 
or infectious pressure. In the clinic, pre-exposure, co-infection, 
and/or co-morbidity conditions can be expected to have an impact 
on susceptibility and also vaccine efficacy (36). The TBVAC2020 
consortium, which at this point just passed mid-term of its 4-year 
work program, has set out in a specific WP to develop and refine 
models toward various clinically relevant conditions. Grossly, we 
have defined three areas as follows: (A) modeling vaccination 
conditions post-Mtb exposure, (B) modeling disease risk factors 
and clinically relevant conditions, and (C) refinement of exist-
ing models. With an eventual goal of implementing alternative 
models to provide proof-of-concept in support of preclinical vac-
cine development and candidate portfolio management, animal 
studies are explicitly useful also for investigating fundamental 
aspects of TB infection and immunity and may contribute to the 
identification and validation of BM candidates as one of the other 
key objectives of this consortium (covered in WP5).
Modeling vaccination Conditions  
Post-Mtb exposure
From the first year of the program onward activities have been 
initiated (i) to test alternative approaches to provoke reactiva-
tion of low-dose disease in mice and in the face of vaccination, 
(ii) to set up a so-called Cornell-type of post-exposure vaccina-
tion in guinea pigs, and (iii) to evaluate Mtb infection in cattle as 
a novel model of latent Mtb infection for post-exposure vaccine 
evaluation.
While both spontaneous reactivation and immunosuppres-
sive regimens pose shortcomings in the context of modeling and 
testing efficacy of post-exposure vaccination strategies, we have 
explored “energy deprivation” by protein malnutrition (PEM) as 
an alternative to reactivate TB in mice. It was demonstrated that 
PEM, both in the infection and the vaccination phase, abrogates 
vaccine-induced protection, which is reversible by protein sup-
plementation (37). Abrogation of vaccine efficacy correlated 
with the loss of cytokine positive memory populations from the 
periphery and in particular with the loss of IL2 producing CD4+ 
T cell subsets. Although prototype vaccination did overcome and 
protect from malnutrition-induced reactivation, the results also 
suggested that more stringent malnutrition conditions would 
be required to lend more robustness to this model. In the light 
of animal welfare, however, this line will not be pursued. In the 
guinea pig model, the test conditions for in vivo bacterial expan-
sion (regrowth) after antibiotic treatment have been established. 
The dynamic window of this model has been established using 
RUTI™ as a therapeutic vaccine candidate (38), with promising 
results that merit a follow-up study testing other candidates. This 
model may also be a valuable tool for studying and developing TB 
treatment regimes toward drug-resistant TB. Using Mtb (rather 
than M.bovis) to infect cattle provides great potential for obtain-
ing a large (outbred) animal model that is hall-marked by latent, 
low burden Mtb infection and that can be manipulated to induce 
disease reactivation (39). Although in its early days, if successful, 
this effort may provide a platform for analyzing vaccine efficacy 
in a state of latent TB infection and a perspective on identification 
of associated BMs.
Toward Modeling of Risk Factors and 
Clinically Relevant Conditions
The workplan comprises the following conditions: (i) exploring 
differential monocyte/myeloid phenotypes in mice as a param-
eter of disease susceptibility, (ii) co-morbidity of obesity either or 
not in inflammation-prone mice and with multiple consecutive 
challenge conditions, (iii) stringent mouse modeling against 
clinical (Beijing-type) isolates of Mtb, and (iv) simian immuno-
deficiency virus co-infection in NHPs.
While monocyte frequency and phenotype have been associ-
ated with TB risk in the clinic (40–42), different strains of mice, 
which express differential profiles of myeloid cell compartment 
markers, have been used in BCG vaccination and protection 
experiments. In the face of variable efficacy in a selected range 
of host strains (43), flow cytometric analyses allow correlation 
of monocyte numbers and (functional) phenotypes with BCG-
induced efficacy. Also in mice, we have exploited commercial 
high-fat diet to induce obesity (not formally characterized as a 
diabetic condition, yet showing impaired glucose tolerance). In a 
matrix-type study design, varying parameters relating to obesity, 
low-dose aerosol infection and multiple consecutive infections, 
disease susceptibility, and standard BCG efficacy are investi-
gated. Further to experimental TB modeling in mice, multiple 
clinical isolates with different clinical and genotypic appearance 
were cultured and selected from Beijing, Beijing subtype and 
non-Beijing strains. Supported by molecular typing and in vitro 
virulence analyses using bone-marrow-derived macrophage 
cultures, seed lots were prepared for future vaccine evaluation 
testing from a limited number of strains, as well as a standard 
laboratory strain for comparison. Mouse infection experiments 
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further corroborated the notion that HN878 and M2 strains 
provide highly pathogenic phenotypes both in vitro and in vivo 
(44, 45). A study toward the definition of a TB/HIV co-infection 
model for vaccine evaluation using TB/SIV co-infection in NHP 
is in progress. All cynomolgus macaques in the study controlled 
a stable low grade chronic Mtb infection for 16 weeks prior to 
SIV challenge. Co-infection with SIV leads to a reduction in CD4 
T cells and trends for higher disease burden with mycobacteria-
specific and SIV-specific immune responses detected in all co-
infected macaques.
Refinement of existing Models
To strengthen the use of the well-established guinea pig model 
in TB vaccine R&D, methods have been developed to quantify 
and characterize antigen-specific T  cell responses. Specific 
T  lymphocytes are expanded, isolated, and re-stimulated to 
investigate functional markers by quantification of cytokine and 
other effector molecule expression levels. Further vaccine experi-
ments will assess anti-mycobacterial immunity by these new tools 
in this stringent model. This refinement is particularly relevant 
for the analysis of unconventional vaccine candidates based on 
mycobacterial lipid antigens. Guinea pigs, in contrast to mice, 
do express a functional CD1 type 1 antigen presentation system, 
thus, representing the only small animal model to study these 
unconventional vaccine research approaches.
As another means of refinement, new NHP modeling tools 
and conditions are being established for refined infectious 
challenge, advanced flow cytometric analyses (including that 
of innate subsets), and advanced imaging of disease and host 
response dynamics by PET/CT imaging (46). To the latter in 
particular, the consortium also collaborates with external part-
ners in a global network [governed by the Bill & Melinda Gates 
Foundation (BMGF)3]. The work in NHP so far has revealed 
pro- vs. anti-inflammatory/regulatory signatures that correlate 
with disease susceptibility and that hint toward a key role for 
differential innate immune orchestration. While, typically, NHP 
studies and protective efficacy assessment rely on measuring 
peripheral immunity and parameters of disease reduction, we 
currently apply standard and non-conventional vaccination to 
investigate early and local, innate and adaptive immune response 
parameters, and toward possible proof-of-concept for protection 
against infection (rather than protection against disease) in this 
highly susceptible species.
Overall, new modalities for modeling reactivation of disease 
(rather than primary infection) have been evaluated and are 
ongoing in different species (mouse, guinea pig, and cattle). More 
stringent and clinically relevant conditions for preclinical in vivo 
analysis of vaccines have been established. Benchmarking by 
standard/prototype vaccination is ongoing in mice, guinea pigs, 
and NHP toward diversification and refinement of preclinical 
vaccine R&D strategies. All these activities, as a two-pronged 
attack, add to our continuous and concerted effort to strengthen 
preclinical evaluations of candidates as well as our basic under-
standing of pathogen–host interaction in TB.
3 https://www.ctvd.co.
wP3 PReCLiNiCAL TeSTiNG AND 
DeveLOPMeNT OF New TB vACCiNe 
CANDiDATeS
The overall aim of WP3 is to support and facilitate the progres-
sion of vaccine candidates from discovery through to preclinical 
development. This is achieved in two sub-WPs. WP3.1 enables 
the selection of successful candidates through comparative head-
to-head testing in standardized animal models. These studies 
provide crucial information for vaccine developers and also 
support activities in WP3.2 which aim to take the prioritized, 
most promising preclinical TB vaccine candidates and acceler-
ate their advancement through the TB vaccine pipeline. WP3.2 
provides expertise in all aspects of product development which 
enables relevant advice via tailor-made Product and Clinical 
Development Teams (P&CDTs) to be given to developers in 
order to advance their candidates in an efficient manner. Specific 
issues are identified and guidance/recommendations are given to 
developers. Close interaction between the sub-WPs is essential 
to ensure effective use of resources and this is facilitated by the 
Portfolio Management Committee (PMC) (WP6).
wP3.1 HeAD-TO-HeAD TeSTiNG iN 
STANDARDiZeD PReCLiNiCAL MODeLS
Demonstration of the safety, immunogenicity, and efficacy of 
vaccine candidates in animal models is required for preclinical 
development. This WP aims to provide evidence that the candi-
date is safe and elicits:
•	 an immune response that can be justified as being anti- 
mycobacterial and is of appropriate magnitude in terms of 
strength and duration, compared to a benchmark such as BCG;
•	 a protective effect against experimental challenge with Mtb 
which is demonstrated by a quantifiable reduction in disease 
burden compared to no treatment and/or BCG or another 
relevant benchmark vaccine.
Systematic, independent, and objective comparison of TB 
vaccines in well-characterized animal models enables the iden-
tification of the vaccines that have the greatest potential to be 
immunogenic and to show efficacy in the clinic. WP3.1 provides 
capacity for animal testing, building upon the concept that was 
developed in previous FP5, FP6, and FP7 projects for head-to-
head comparisons of candidates in standardized animal models. 
In addition, there is an aim to offer models that better represent 
the target product profiles of the vaccines being developed.
The objective of WP3.1 is to compare and prioritize vaccines 
from the candidate discovery work package of this project (WP1) 
which supports decision-making at the individual partner and 
WP level and provides objective evidence for decision-making 
in portfolio management using the stage-gating criteria (WP6). 
Wherever feasible, samples are retained for selected evaluation 
of potential correlates of protection (CoP; WP5). The partners 
providing the models all have experience and a track record in 
TB R&D and importantly are recognized providers of unbiased, 
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high quality evaluation of vaccines in their respective models. 
A summary of each of the models provided is given below.
SCiD Mouse Model for Safety  
of Live vaccines
Assessing the residual virulence of live vaccine candidates in 
the context of an immunodeficient host is an essential part of 
modern pre-clinical vaccine evaluation. Vaccine candidates are 
administered into severe combined immune deficient (SCID) 
mice using methodologies and study designs described (47). This 
has become an accepted standard for safety evaluation of live 
vaccines (48) and has been successfully used to benchmark the 
safety of live vaccine candidates against BCG.
Standard immune Competent Mouse 
Model for Protective efficacy
The first screen of vaccine candidates for immunogenicity and 
efficacy is usually performed by individual laboratories during 
the discovery phase. Capacity has been provided in WP3.1 for 
testing in a standard mouse model to assist laboratories, which 
lack facilities for Mtb challenge studies, and/or to facilitate 
decision-making within the project. For example, within WP1 
where different adjuvants and delivery systems are being devel-
oped, a head-to-head comparison could allow prioritization 
based on protective efficacy. The model entails vaccination of 
CB6F1 (H-2b/d) hybrid mice, subsequently challenged with Mtb 
H37Rv via the respiratory route with protection determined by 
bacterial load in lungs and spleen at 6 weeks post infection.
Mouse Model for Protective efficacy 
against Clinical (Beijing) Strains of Mtb
It is important to demonstrate that new TB vaccine candidates can 
protect against challenge with clinically relevant and highly viru-
lent strains of Mtb, including Beijing strains, which are prevalent 
in East Asia. Highly virulent Mtb strains (one Beijing strain and 
one Euro-American lineage, see also activities in WP2), showing 
a lower efficacy of the BCG vaccine (49), are used to challenge 
by inhalation, vaccinated mice (either pre- or post-exposure). 
Protection is determined at 4 weeks and 10 weeks after challenge.
Mouse Model for efficacy of vaccine 
Candidates Given Post-exposure
Robust animal models are needed to be able to test that vaccines 
can be safe and efficacious in individuals who are already infected 
with Mtb. A well-established mouse model for therapeutic vac-
cination is provided. This model has been validated previously 
(50, 51). The model involves aerosol infection followed by 
chemotherapy administered for 8 to 10  weeks post-infection 
with vaccination within weeks 12–17 and efficacy determined at 
week 23.
Guinea Pig Model for Protective efficacy
The aerosol infection guinea pig model of TB has been widely 
used to determine vaccine efficacy, being regarded as a more 
stringent test than the standard mouse model. Data generated 
in previous EU-funded consortia demonstrated the utility of a 
standardized model, where the main read-out of efficacy is reduc-
tion in bacterial load, compared to control groups at 4  weeks 
post-challenge (47).
Mouse immunogenicity for  
Formulation Studies
In combination with a vaccine formulation service where TB 
vaccine candidates are optimized with various type of adjuvants, 
there is provision of immunogenicity data in a harmonized 
mouse model which enables rational selection through compara-
tive assessment of promising adjuvanted TB vaccine candidates.
To provide further flexibility in the preclinical evaluation of 
candidates, an aim of the project is to develop new animal models 
and improve read-outs of existing models such that they reca-
pitulate a broader range of relevant conditions as they appear in 
the human populations being targeted. This model development 
is being conducted in WP2 with a view to incorporate a newly 
developed animal model or readouts into WP3.1 in order to offer 
a wider range of head-to-head testing.
PROGReSS TO DATe
Up to June 2017, 51 tests (comprised of 21 different vaccine can-
didates/approaches) of safety, immunogenicity and/or efficacy 
have been completed (33 tests) or are on-going (18 tests) in the 
various models. Outcomes of completed studies are summarized 
below:
•	 In the standard mouse or guinea pig challenge models, three 
candidates have shown protective efficacy and four were not 
efficacious.
•	 In post-exposure or Beijing challenge models, eight candidates 
afforded significant protection, four gave partial protection 
and three did not protect.
•	 Safety data on four candidates using the SCID mouse model, 
showed that three were attenuated.
•	 Data on the stability and immunogenicity of seven adjuvant 
formulations have been provided for one antigen.
These data (both positive and negative) have informed the 
portfolio management (WP6) and supported the vaccine dis-
covery activities (WP1).
wP3.2 PReCLiNiCAL DeveLOPMeNT
The main objective of this sub work package is to manage and 
facilitate the advance of the preclinical development pathway of 
new TB vaccine candidates. It supports the progression of the 
pipeline by advancing candidates prioritized through preclinical 
toward an early clinical stage of development using a portfolio 
management approach (as described in WP6). Tailor-made 
P&CDTs, including experts in regulatory, manufacturing, and 
clinical studies of vaccines, are established together with the 
selected vaccine developers. Currently, there are four vaccine can-
didates in preclinical development. For HBHA and BCGΔzmp1 
candidates, joint P&CDTs with Aeras (as part of the joint global 
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effort in TB vaccine development) have also been established to 
support these candidates in the context of the activities of this 
project. More information about the P&CDT can be found in the 
chapter describing WP6.
Heparin-Binding Hemagglutinin
Heparin-binding hemagglutinin (52, 53) in combination with 
adjuvant giving the best level of immunogenicity and protec-
tion in animal models and in ex vivo models are compared and 
evaluated, in order to select the best combination. For vaccine 
optimization, a thermo-stabilized form of HBHA, which will 
make it less dependent on the cold chain and, therefore, more 
logistically accessible for most of the TB endemic countries, will 
also be developed and evaluated.
Recombinant BCGΔzmp1
Confirmation of identity, drug susceptibility and genetic stability 
of BCGΔzmp1 mutant (54, 55) strain(s) over serial passages (>12) 
has been achieved. An unmarked Δzmp1 mutant in a background 
strain with full background history and freedom to operate in 
terms of product development to licensure has been generated 
and characterized with respect to safety, immunogenicity and 
efficacy in various animal models within the consortium.
Combination of M72/AS01e and ChAd3M72
The M72 vaccine, containing both human CD4+ and CD8+ 
T cell epitopes, is an adjuvanted (AS01E) fusion protein vaccine 
candidate and has been evaluated in clinical trials (56, 57). The 
use of ChAd vector has been shown to elicit strong CD8+ T cell 
responses. The ChAd3M72, using a viral vector for delivery, is 
developed as a boost for M72/AS01E prime. This heterologous 
prime boost approach has been assessed in a mouse model to 
induce a higher number of antigen-specific CD4+ and CD8+ 
T cells in the lung and peripheral blood with a different profile of 
CD4+ T cell polyfunctionality as compared to two doses of M72/
AS01E (unpublished data).
MvA–TB vaccine Candidates
Preclinical development of the MVA vectors expressing multiple 
Mtb antigens specifically targeted as a therapeutic vaccine is to 
improve treatment of active TB (in particular linked to drug-
resistant strains) and to prevent reactivation and/or re-infection 
in the adult population, in particular from endemic countries. 
Genetically stable MVA–TB vaccine candidates (58) are cur-
rently being evaluated using different murine post-exposure 
models (with collaborators in the USA and Spain). In addition, 
a manufacturing process for MVA–TB from a cell line and not 
primary cell cultures (NIH grant with Emergent BioSolutions) is 
also under development.
Additional support service is provided for specific vaccine for-
mulation optimization and characterization of TB vaccine candi-
dates selected within the consortium (59). A panel of adjuvants 
(including emulsions, liposomes, aluminum salts, TLR agonists, 
and others) and different production methods are available for 
formulation. This will allow vaccine developers to investigate and 
improve the compatibility and stability of their antigen with dif-
ferent adjuvants, and to define the optimal production methods 
to generate physico-chemically stable and immunogenic TB 
vaccine candidates.
WorkPackage 3 provides a valuable resource for vaccine devel-
opers especially those from an academic environment to progress 
their vaccine candidates from discovery to the preclinical devel-
opment stage. The developers with selected vaccine candidates 
have access to various preclinical animal models and the support 
of the P&CDT. The advice from the tailor-made P&CDT is not 
restricted to regulatory, manufacturing, and early clinical studies, 
but also includes project management. These activities will lead 
to a more diverse and more promising pipeline of novel vaccine 
candidates at preclinical stages, and subsequently also for early 
clinical stages.
wP4 COMPARATive CLiNiCAL TeSTiNG 
iN TBvAC2020
Early phase I and first-in-man clinical testing is an essential bridge 
between the demonstration of safety and efficacy in preclinical 
animal models and field testing in clinical trials in TB endemic 
countries. Such early clinical testing focuses on evaluating safety, 
usually in healthy adults, and immunogenicity, using a variety of 
standardized immunological assays. The overall concept under-
pinning WP4 is that standardized early clinical testing is essential, 
given the increasing numbers of diverse candidate TB vaccines 
being evaluated in preclinical animal models. There is currently 
a significant portfolio of diverse candidate vaccines in clinical 
and late preclinical development, which illustrates the progress 
made over the last 15 years (60). With the increasing number of 
diverse candidate vaccines currently in preclinical development, 
it is important to develop standardized methods and facilities for 
early clinical testing, in order that the most promising candidates 
can be selected for progression. There will never be sufficient 
resources to progress all the current candidates through to field 
testing in TB endemic countries. The use of standardized clinical 
trial protocols, standardized safety reporting, and standardized 
immunological evaluation according to published recommenda-
tions will allow comparison between different candidate vaccines 
(61, 62). This comparison will facilitate the rational selection of 
which candidates should be progressed to further clinical testing 
and efficacy testing in field trials. The aim of WP4 is to focus 
on early clinical TB vaccine development and to build on the 
successful standardized preclinical vaccine testing developed 
in EC supported FP6 TBVAC and FP7 NEWTBVAC projects. 
Over the last 10 years, the TBVAC/NEWTBVAC consortia have 
conducted many standardized head-to-head preclinical animal 
studies in mice, guinea pigs and NHPs. The data arising from 
these studies have facilitated vaccine selection (63, 64). This WP 
takes this successful approach a step further and applies it to early 
clinical testing.
Furthermore, there is an opportunity provided by this WP 
to embrace human experimental medicine studies, where early 
clinical trials can be used to demonstrate proof-of-concept. An 
example of this would be the evaluation of the safety and immu-
nogenicity of a recombinant viral vector delivered by aerosol, 
compared with systemic administration (65).
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PROCeSS FOR vACCiNe SeLeCTiON
Vaccine candidates are selected for inclusion in this WP by the 
PMC, in conjunction with the TBVI P&CDT. This advice is inde-
pendent of the vaccine developer. TBVI and Aeras have agreed on 
a set of portfolio management criteria which include stage-gating 
criteria (7, 34), and these criteria are used to guide vaccine selec-
tion in this WP4. The data arising from the trials conducted as 
part of this WP4 will be reviewed by the PMC for subsequent 
decisions about progression to safety and immunogenicity trials 
in TB high burden countries. Ongoing interactions with The 
European & Developing Countries Clinical Trials Partnership 
(EDCTP) and clinical sites in Africa, including those that are part 
of the EDCTP Networks of Excellence, will ensure that, subject 
to full and independent peer review, promising candidates are 
progressed as efficiently and effectively as possible in an endemic 
setting. Support and advice by tailor-made P&CDT will be pro-
vided to each vaccine developer to accelerate the development of 
the respective vaccine candidates through phase I/first-in-man 
clinical trial stage.
iMMUNOLOGiCAL evALUATiON
Although we do not have an immunological correlate of protec-
tion with which to guide vaccine design and evaluation, there are 
several well-defined parameters of the host immune response 
which are known to be essential for protective immunity against 
Mtb. The immunological evaluation will be conducted using 
standardized operating procedures (SOP). Assays will include 
ex vivo IFNγ ELISpot assays, whole blood polychromatic flow 
cytometry with intracellular cytokine staining to measure other 
T cell cytokines, including IL-2, TNF-α, and IL17 from antigen-
specific CD4+ and CD8+ T cells, and serological testing for anti-
body responses. The focus of this immunological evaluation is to 
use standardized assays to generate information about immune 
functions considered to be important in protective immunity. 
Work conducted within FP6 TBVAC, FP7 NEWTBVAC, and 
FP7 TRANSVAC has resulted in a harmonized SOP for an 
ex vivo ELISpot, which will be used here (66). In addition, a 
harmonized ICS flow protocol developed in these consortia 
will be used here as well (67). We will not use more exploratory 
assays in this WP, as they are less standardized, but PBMC and 
serum will be stored from all subjects at all time-points using 
harmonized SOP, so that further immunological evaluation can 
be performed as the field of BMs develops. In this regard, this 
WP will work closely with WP5 to monitor progress in the field 
of BM development (4, 5, 40, 41). Furthermore, ongoing work, 
for example, within the infrastructural FP7 EURIPRED project, 
to standardize the PBMC mycobacterial growth inhibition assay 
(MGIA), will be monitored and this assay will be conducted on 
cryopreserved material if the assay is deemed sufficiently fit for 
this purpose (68).
PROGReSS TO DATe
There are two broad categories of vaccines currently in develop-
ment: “live” whole organism BCG replacement vaccines and 
subunit vaccines designed to boost BCG. Some live vaccines are 
also being evaluated as booster candidates (69, 70). It is antici-
pated that both types of candidate vaccines will be included and 
tested within this WP. Centre Hospitalier Universitaire Vaudois 
(CHUV), Leiden University Medical Center and University of 
Oxford clinical trial units will be collaborating in the planning 
and execution of the future candidate vaccine testing. Clinical 
and immunological SOPs have been agreed between the three 
partners. Following an open call to all partners, a first vaccine 
candidate has been selected and is planned to enter into phase I 
testing in CHUV in Q4 2017. It is expected that a second candi-
date will be tested in Q1 2018.
wP5 ReSeARCH iNTO TB BMs AND CoP
Next to TB vaccine development and evaluation, an important 
second TBVAC2020 objective is to identify TB BMs, in particu-
lar CoP. CoP are measurable BMs indicating that the host is 
immune, or protected against developing TB disease. Correlates 
of Risk (CoR) are BM indicating the host has an increased risk 
of developing active TB disease. Such TB BMs can be tran-
scriptomic, cellular, or soluble analytes. The identification of 
CoP in particular will help to develop vaccines that target and 
strengthen protective immunity. Importantly, such correlates 
will facilitate the selection and prioritization of candidate TB 
vaccines for human efficacy testing, and will reduce the pro-
tracted time scale, size, and expenses of human efficacy trials 
by allowing the demonstration of vaccine immunogenicity and 
potential efficacy at an early stage. In addition, CoP will permit 
selection of antigens that induce protective immune responses, 
optimization of dose, vehicle, adjuvants, and immunization 
schedules of new candidate vaccines at an early stage and, thus, 
minimize the need for preclinical animal studies. WP5 has a 
strategically designed workflow, which combines TB BM discov-
ery with parallel-specific assay development, followed by testing 
and validation in carefully characterized, complementary and 
unique human cohorts from genetically diverse populations. 
WP5 involves key partners from European, African, and East 
Asian laboratories.
This WP first aims to develop core assays for measuring CoP 
and CoR (#1 in Figure  2) and to evaluate these in carefully 
characterized, unique human cohorts from genetically diverse 
populations (#2 in Figure 2). Complementary to these efforts is 
the discovery of new TB BMs, using innovative approaches (#3 in 
Figure 2). A long-term goal is to move the best performing cor-
relates forward toward validated immune correlate assays, ideally 
in the format of point-of-care tests for use in areas with high TB 
burden. Future activities will include active engagement of assay 
developers. Finally, the WP5 is building a database to capture the 
most important (transcriptomic) TB BMs (#4 in Figure 2), and 
there are close interactions between this WP and other efforts in 
this area.
SPeCiFiC OBJeCTiveS OF wP5
The first key objective is the development, evaluation, and improve-
ment of core assays measuring CoP in TB. To identify TB 
FiGURe 2 | Schematic representation of research priorities and connectivity in WorkPackage 5.
10
Kaufmann et al. TBVAC2020
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1203
vaccine-induced CoP a protective vaccine is needed, but with the 
exception of BCG in settings where it does induce protection, this 
is not yet available. As BCG is able to induce partial protection, 
studies dissecting BCG-induced BMs are part of WP5. Moreover, 
a number of candidate correlates have recently emerged: BCG-
vaccinated TB-protected South African infants had higher 
numbers of IFNγ-producing cells, and antibodies to Mtb anti-
gen Ag85A also correlated with reduced risk of developing TB 
(40, 41). Other candidate CoR have been emerging (71), includ-
ing myeloid/lymphoid (M/L) ratios (72), inflammation signaled 
by activated CD4+ T cells (40, 41), an IL13/AIRE ratio in HIV 
Mtb co-infected individuals (73), the lack of IFNγ responses to 
HBHA (74, 75), and a 16-gene based transcriptomic GC6/ACS 
CoR signature (76) found in large cohort studies in Africa. In 
other joint work by WP5 partners, diagnostic transcriptomic- or 
serum host protein signature-based algorithms were discovered 
that have powerful differential diagnostic value in diagnosing TB 
in both adults and children in Africa (77–79). Several research 
groups in WP5 are involved in efforts to further validate these 
correlates in larger, independent cohort studies.
In parallel to attempts identifying CoP, WP5 participants 
are developing unbiased, functional measures of human pro-
tective responses. One example of such an assay is the in vitro 
MGIA (68). In BCG-vaccinated infants in the UK, there was 
an increased ability to control the growth of BCG following 
BCG vaccination (43). Other “unbiased” assays include global 
immune-, gene expression-, and proteomic profiling-assays, 
which are being evaluated against outcome of infection or 
vaccination in clinical cohorts. We anticipate that the develop-
ment and optimization of novel functional read-outs of anti-
mycobacterial immunity will help identifying novel correlates, 
and may lead to deeper insights into potential mechanisms 
that control mycobacterial outgrowth. Collaborative efforts are 
ongoing with other EC projects, such as the FP7 EURIPRED 
Infrastructure project, as well as with EDCTP-funded work that 
focuses on TB BMs (PREDICT TB and SCREEN TB projects). 
H64 + CAF01
    SSI, TBVI
FiGURe 3 | TBVI vaccine pipeline, overview of the current tuberculosis (TB) vaccine candidates in the development pipeline, per text box: acronym vaccine 
candidate, development partners.
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FiGURe 4 | TBVAC2020 management infrastructure.
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Together, critical assays and assay variables are being identified 
to enable the development of improved, quantitative second 
generation assays. MGIA assays are also being studied for 
utility in analyzing cellular activity in human Purified Protein 
Derivative of Mtb suction blister models, in broncho-alveolar 
lavage (BAL) samples from aerosol BCG-infected volunteers 
and in the NHP model (80).
The second objective of WP5 is the evaluation of these core 
assays in samples from clinical cohorts. Such cohorts that have 
been collected include:
 1. samples from BCG-vaccinated individuals (adults, children, 
neonates) from settings where BCG gives good protection 
against TB (northern Europe);
 2. samples from trials with new candidate TB vaccines [includ-
ing the MVA85 efficacy trial (81) and a recent MTBVAC 
trial (82)];
 3. samples from TB patients with active disease (pre, during, and 
post treatment);
 4. samples from latently TB infected individuals (LTBI), includ-
ing long-term tuberculin skin test (TST) positive- as well as 
TST-negative- non-progressors;
 5. samples from LTBI subjects co-infected with helminths pre- 
and post- anti-helminthic treatment;
 6. samples from HIV-infected (immune-suppressed) Mtb co-
infected subjects;
 7. samples from BCG challenge models; and
 8. samples and data from the unique longitudinal GC6-74 
TB-progressor cohort (76).
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The unique cohorts and sample banks suitable for the meas-
urement and evaluation of correlates are available for study 
in WP5 and are being further expanded, including cohorts 
with long-term longitudinal follow-up. Multiple cohorts have 
been included to represent geographical, ethnic, and epide-
miological diversity, with sites from South Africa, Malawi, The 
Gambia, Uganda, South Korea, Western/Southern Europe (UK, 
Netherlands, Belgium, Italy) and Eastern Europe (Belarus). This 
will also make it possible to test whether TB BMs, including CoR 
and CoP, show variation by population due to specific epidemio-
logical settings.
The third objective of the WP5 is the discovery of new TB candi-
date BM using innovative approaches. Given the lack of CoP, BM 
discovery is needed to fill the TB BMs pipeline with new candidates. 
It is likely that multi- rather than single parameter signatures, or 
complex functional assays will be needed to capture the complexity 
and dynamics of human protective immunity to Mtb. Discovery 
approaches are focusing on both host and pathogen response 
during the different phases of infection. These include global tran-
scriptomics, proteomics, metabolomics, hematopoietic (myeloid) 
progenitor analyses, epigenetic, and cellular approaches. In other 
projects partners are developing intradermal as well as aerosol 
BCG controlled human infection models (CHIM). Such studies 
will allow for identifying and measuring immune correlates, and 
help with correlating in vivo with in vitro results, e.g., results from 
CHIM with corresponding MGIA studies. To date, significant 
progress has been made in transcriptomic marker identification in 
several cohorts, with further data analysis and validation ongoing.
Assays have also been selected to survey the wider global space 
in the immune response to Mtb rather than the traditional focus 
on T cells and cytokines, similar to approaches in HIV correlates 
research. Different compartments of the “immune space” being 
investigated include adaptive immunity (T cells, B cells, immune 
regulatory cells), innate immunity [innate lymphocyte-subsets, 
DC-subsets, macrophages (83), tolerogenic monocytes, myeloid-
derived suppressor cells (84)], NK cell subsets, dysregulation of 
apoptosis or autophagic flux (85), the role of particular immu-
nometabolomic and proteomic markers (86) (in blood or other 
body fluids) etc. Recent findings point to an important role for: 
antibodies and B cells in TB (40, 41, 87, 88); a role for HLA-E 
restricted Mtb specific CD8+ T cells (89, 90); and polycytotoxic 
LAM-specific T cells (91).
The longer-term strategy of WP5 is to select the most promising 
markers and assays for further development toward user friendly, 
preferably point of care, tests (92). Partners have expertise in 
downstream assay development such as lateral flow assays (86) 
and simplified transcriptomic assays (71). Recent novel work on 
mathematical modeling of vaccine immune responses has shown 
that models can predict dose–response relationships (93).
An important point is that TB BM assays may need to be 
adapted to specific types of TB vaccines (e.g., live vs. subunit) or 
depending on the antigen and delivery system selected. This may 
necessitate “tailor made” sets of BMs, for which TBVI is setting 
up a BM Development Team (BDT).
Finally, WP5 is building a TB transcriptomic biomarker 
database, to be a helpful resource for the TB BM community to 
provide a basis for “tailor made” TB vaccine biomarker selection, 
and to complement a TB diagnostic BM database as a valuable 
resource for future research (94).
WorkPackage 5 also links to other activities in TBVAC2020, 
including animal models (mice, NHPs) and human clinical 
vaccine trial related TB BM assays; and some of WP5 partners 
actively participate in these activities.
CONCLUDiNG ReMARKS
WorkPackage 5 aims to discover new TB BM (of protection and 
TB risk) using innovative approaches including omics studies; 
to develop and improve key functional assays; and, importantly, 
to initially validate and then cross-validate candidate TB BMs in 
human cohorts (95). The long-term goal is to test and provide 
data on the biological validity of the BMs discovered and the 
assays developed using cohorts in whom protection will be 
demonstrable and to evaluate them against clinical endpoints 
(including incident TB and Mtb infection). The unique combina-
tion of researchers, expertise, technologies and human cohorts 
for validation studies is key to the success of this ambitious task.
wP6 PORTFOLiO MANAGeMeNT
introduction
Globally, TB vaccine R&D has made tremendous progress over 
the last 10–15 years, from only a few TB vaccine candidates in 
the pipeline 15 years ago to currently more than 25 candidates in 
early development and 13 candidates being evaluated in clinical 
stages.4 Despite this progress, significant gaps remain that ham-
per efficient and effective TB vaccine development. Challenges 
include the establishment of:
 (i) a more diverse pipeline to support successful delivery of new 
TB vaccines for all populations;
 (ii) validated pre-clinical models predicting efficacy in humans;
 (iii) validated humanCoP;
 (iv) sufficient efficacy trial capacity in TB endemic areas.
TBVAC2020 directly addresses most of these challenges by 
supporting activities which will diversify and innovate the TB 
vaccine pipeline (WP1); by developing standardized animal 
models allowing head-to-head comparison of candidate vaccines 
for different disease targets (WP2); by accelerating promising pre-
clinical vaccine candidates (WP3); by innovating clinical design 
and conduct phase I experimental medicine studies (WP4); and 
by developing CoP (WP5). The progress that TBVAC2020 is mak-
ing in addressing these challenges shows that new TB vaccines 
are feasible. The continuation of scientific progress will require a 
sustained commitment over the long term for funding TB vaccine 
R&D by the EU and its member states. It is furthermore impera-
tive that the TB vaccine R&D community, in turn, manages the 
global TB vaccine pipeline as efficiently and as coherently as 
possible and conducts a rationale selection of TB vaccine R&D 
efforts through a portfolio management approach.
4 http://www.tbvi.eu/what-we-do/pipeline-of-vaccines/.
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Objective
It is the objective of WP6 of the TBVAC2020 project to contrib-
ute to establishing a diverse and innovative portfolio of new TB 
vaccine candidates through a portfolio management approach: 
an objective and transparent process to prioritize and accelerate 
vaccine candidates in this project (Box 1).
Portfolio Management
Portfolio management is an efficient and effective mechanism to 
advance the vaccine pipeline. It is a quality decision-making pro-
cess seeking to maximize probability of success against accept-
able cost and risk. Portfolio management ensures alignment 
of vaccine candidates and resources, and ensures an optimal 
BOx 1 | Role of TBVI in accelerating the discovery and development of new tuberculosis (TB) vaccines in TBVAC2020.
TBvi
TBVI is an innovation partnership that works to discover and develop new safe, effective, and affordable TB vaccines.
TBVI consist of two parts:
 1. The TBVI R&D partners including more than 50 partners from academia, research institutes, and private industry in the TB vaccine field from about 20 countries in 
Europe, North America, Africa, Asia, and Australasia.
 2. The TBVI organization that is a support structure to vaccine researchers and developers to facilitate the discovery and development of new, safe, and effective 
TB vaccines and biomarkers (BMs) for global use. TBVI brings together R&D organizations, scientists and industry partners in one network in order to facilitate 
optimal development of vaccine candidates in clinical settings. The organization provides independent technical and scientific advice to its R&D partners and 
funders.
TBVI provides a range of essential services to support its R&D partners as well as funders, technical agencies, and other stakeholders. These services include:
 1. Technical support,
 2. Knowledge development, exchange, and networking,
 3. Project identification, design, development, and management,
 4. Resource mobilization.
Contribution to the global TB vaccine pipeline
The support activities of TBVI to its TB R&D partners have been instrumental in the development of the current global TB vaccine pipeline. By facilitating 
discovery, preclinical, and early clinical development, TBVI has contributed to moving 50% of candidates globally to clinical stages of development 
(Figure 3).
 1. Technical support services
TBVI provides technical support for product and clinical development through its independent Product and Clinical Development Teams (P&CDT). This team helps 
manage the development of the candidates prioritized by the portfolio management process (see chapter WP6) while researchers and developers move their 
candidates from concept to clinical development. The P&CDT also provides advice on the experimental design of preclinical studies conducted in WorkPackage 
(WP) 3 and on the clinical design of the phase I trials conducted in WP4 (For more information on P&CDT see: http://www.tbvi.eu/about-us/organisation/
product-and-clinical-development-team/).
 2. Knowledge development, exchange, and networking.
To optimize the discovery and development of new TB vaccines and BMs, TBVI facilitates and supports the generation of new knowledge and exchange among 
R&D partners by promoting knowledge-sharing through scientific meetings and workshops, publication in scientific and non-scientific journals, formal and informal 
networking. Through joint collaborative working with open sharing of data prior to publication, a network of trust and respect has been established between TB 
vaccine R&D groups throughout Europe and the world. The annual project meetings are a key example of this trust and open data sharing within the network. 
The annual project meeting in 2017 of the TBVAC2020 consortium organized in combination with the TBVI annual symposium brought together 163 participants 
from 19 countries worldwide. Beside the project R&D partners and linked industry partners, the representatives from many partner organizations, like EC, Aeras, 
European & Developing Countries Clinical Trials Partnership, Bill & Melinda Gates Foundation (BMGF), World Health Organization, European Research Infrastructure 
for Translational Medicine and European Vaccine Initiative attended this meeting.
 3. Project identification, design, development, and management.
TBVI initiates new projects when new funding opportunities arise. In line with its R&D strategy, TBVI applies a bottom-up process working closely 
with its partners to develop project proposals. An example of this process was the creation of the TBVAC2020 project proposal. TBVI identified the 
European Commission (EC) Horizon 2020 call on new TB vaccines. In consultation with leading experts in the field, TBVI identified the areas and 
scope of work to be included in the project proposal. To enable the involvement of new partners and to receive the best new ideas, TBVI launched 
an open call for Expression of Interest (EoI). Over 100 EoI letters were received. A project selection committee selected the best project proposals 
based on predetermined selection criteria. This finally resulted in EC awarding €18.2 million for the TBVAC2020 project. Additional funds from the 
Swiss, Korean, and Australian governments complemented the project budget to a total of €24.6 million (http://horizon2020projects.com/sc-health/
tb-consortium-awarded-e24m-international-grant/).
TBVI is the coordinator of the TBVAC2020 project and provides essential services to contribute to successful completion of the pre-set project deliverables 
and milestones, to increase the overall impact of the project, and to ensure coordination and linkages between TBVAC2020 and other TB vaccine R&D initiatives. 
To ensure efficient and effective management of the project, TBVI has established and implemented the management infrastructure (Figure 4). The project 
infrastructure is composed of the Steering Committee, the Project Management Team (PMT led by the Coordinator) and the following three advisory groups: 
Portfolio Management Committee, Ethics advisory group, and External Advisory Committee.
 4. Resource mobilization.
TBVI mobilizes resources for its R&D partners. TBVI was able to leverage funding from this project with other funders including Norwegian Agency for Development 
Cooperation, Department of International Development and BMGF. This enabled additional and accelerated development of two preclinical and three clinical stage 
candidates, of two novel and refined preclinical models, and made it possible to continue key research and development activities on correlates of protection of 
7 partners.
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balance between them (96). The aim of WP6 is to contribute 
to the establishment of a balanced and diverse portfolio of pre-
clinical and early clinical TB vaccine candidates with prospective 
applications in infants, adolescents, and adults that focus on 
either preventing active TB disease or improving treatment of 
TB disease.
The portfolio management approach applied in TBVAC2020 
is based on three sets of criteria:
 1. Stage-gating criteria. Stage-gating criteria provide a linear 
assessment of each individual candidate to determine if there 
is sufficient robust evidence to support advancement to the 
next stage of development (34, 97).
 2. Portfolio assessment. Priority-setting assessment criteria 
allow comparison of similar vaccine candidates in a portfolio 
to select and deselect candidate(s), especially those at the same 
developmental stage.
 3. Entry of new candidates. Entry criteria allow assessment of 
new candidates into the portfolio to create more diversity and 
balance in the portfolio and to increase chance of success.
An independent PMC uses these three sets of criteria to 
monitor and provide advice to the Steering Committee of 
TBVAC2020 on the vaccine pipeline of the project. It moni-
tors discovery activities in WP1 and WP2, provides advice on 
entrance of new candidates, advises on selection and priority 
of vaccine candidates for evaluation in preclinical models or to 
support their preclinical development (WP3), and for selection 
and evaluation of candidates in clinical trials (WP4). During 
the first 30  months of the TBVAC2020 project, PMC advised 
on the selection of 21 candidate vaccines for evaluation in 6 
head-to-head preclinical models, 4 candidates for receiving 
support for preclinical development among others formulation, 
Good Manufacturing Practice (GMP) and developing a product 
development plan, and two candidates for evaluation in a phase 
I clinical trial. During this period, PMC deselected six vaccine 
candidates for evaluation in the head-to-head preclinical models 
and 1 candidate was deselected for evaluation in a phase I clinical 
trial. It is the intention that PMC of WP6 will integrate with the 
Global Portfolio Review Committee (GPRC) for the Global TB 
vaccine Partnership (GTBVP) once this entity is established. The 
GPRC aims to provide advice from a global perspective, with 
regard to selection or deselection of vaccine candidates for sup-
port to the next step in development.
CONTRiBUTORS: PARTiCiPATiNG 
iNveSTiGATORS iN TBvAC2020 
CONSORTiUM
The TBVAC2020 consortium consists of 42 partner institutions 
from 15 countries, including 10 from Europe, 1 from USA, 1 from 
South Korea, 1 from Australia, 1 from the Gambia, and 1 from 
South Africa represented by the following members:
Australia: Warwick Britton (W.J. Britton), University of 
Sydney, Autralia; Jamie Triccas (J.A. Triccas), University of 
Sydney, Autralia; Claudio Counoupas (C. Counoupas), University 
of Sydney, Autralia. Belgium: Johan Grooten (J. Grooten), Ghent 
University, Belgium; Marie-Ange Demoitie (M.A. Demoitié), 
GSK Biologicals, Belgium; Marta Romano (M. Romano), 
Scientific Institute of Public Health (WIV-ISP), Belgium; Kris 
Huygen (K. Huygen), Scientific Institute of Public Health (WIV-
ISP), Belgium; Hermann Giresse Tima (HG. Tima), Scientific 
Institute of Public Health (WIV-ISP), Belgium; Francoise Mascart 
(F. Mascart) , Université Libre de Bruxelles, Belgium. Denmark: 
Peter Andersen (P.L. Andersen), Statens Serum Institut (SSI); 
Claus Aagaard (C. Aagaard), Statens Serum Institut (SSI); 
Dennis Christensen (D. Christensen), Statens Serum Institut 
(SSI); Morten Ruhwald (M. Ruhwald), Statens Serum Institut 
(SSI); Thomas Lindenstrom (T. Lindenstrom), Statens Serum 
Institut (SSI). France: Olivier Neyrolles (O. Neyrolles), Centre 
National de la Recherche Scientifique (CNRS); Pierre Charneau 
(P. Charneau), Institut Pasteur Paris; Christophe Guilhot (C. 
Guilhot), Centre National de la Recherche Scientifique (CNRS); 
Antonio Peixoto (A. Peixoto), Centre National de la Recherche 
Scientifique (CNRS); Martine Gilleron (M. Gilleron), Centre 
National de la Recherche Scientifique (CNRS); Isabelle Vergne (I. 
Vergne), Centre National de la Recherche Scientifique (CNRS); 
Camille Locht (C. Locht), Institut Pasteur de Lille; Roland 
Brosch (R. Brosch), Institut Pasteur Paris; Genevieve Inchauspe 
(G. Inchauspé), Transgene; Stephane Leung Theung Long (S. 
Leung-Theung-Long), Transgene. Germany: Stefan Kaufmann 
(S.H.E. Kaufmann), Max Planck Institute for Infection Biology; 
January Weiner (J. Weiner), Max Planck Institute for Infection 
Biology; Jeroen Maertzdorf (J. Maertzdorf), Max Planck 
Institute for Infection Biology; Natalie Nieuwenhuizen (N. 
Nieuwenhuizen), Max Planck Institute for Infection Biology; 
Max Bastian (M. Bastian), Friedrich-Loeffler-Institut; Steffen 
Stenger (S. Stenger), University of  Ulm; Stephanie Kallert (S. 
Kallert), University of  Ulm. Ireland: Stephen Gordon (S.V. 
Gordon), University College Dublin. Italy: Nadia Caccamo 
(N. Caccomo),  Azienda Ospedaliera Universitaria Policlinico 
“Paolo Giaccone” di Palermo; Delia Goletti (D. Goletti), 
IRCCS Lazzaro Spallanzani; Roberto Nisini (R. Nisini), Istituto 
Superiore Di Sanità (ISS). Republic of Korea: Sung Jae Shin (S.J. 
Shin), Yonsei University College of Medicine; Sang Nae Cho 
(Ray) (S.N. Cho), Yonsei University College of Medicine; Hyejon 
Lee (H. Lee), International Tuberculosis Research Center; Ino 
Choi (I. Choi), International Tuberculosis Research Center. 
South Africa: Alex Sigal (A. Sigal),  Kwazulu-Natal Research 
Institute for Tuberculosis; Thomas Scriba (T.J. Scriba), South 
African Tuberculosis Vaccine Initiative; Gerhard Walzl (G. 
Walzl), Stellenbosch University; Andre Loxton (A.G. Loxton), 
Stellenbosch University; Robert Wilkinson (R.J. Wilkinson), 
University of Cape Town; Katalin Wilkinson (K.A. Wilkinsons), 
University of Cape Town. Spain: Pere-Joan Cardona (P.J. 
Cardona), Fundació Institut d’ Investigació en Ciències de la 
Salut Germans Trias i Pujol; Cris Vilaplana (C. Vilaplana), 
Fundació Institut d’ Investigació en Ciències de la Salut 
Germans Trias i Pujol; Carlos Martin (C. Martin), University 
of Zaragoza; Dessi Marinova (D.V. Marinova), University of 
Zaragoza; Nacho Aguilo (N. Aguilo), University of Zaragoza. 
Switzerland: François Spertini (F. Spertini), Centre Hospitalier 
Universitaire Vaudois; Ruedi Aebersold (R. Aebersold), ETH 
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Zürich – Institute of Molecular Systems Biology; Etienne 
Caron (E. Caron), ETH Zürich – Institute of Molecular Systems 
Biology; Daniel Pinschewer (D. Pinschewer), University of Basel; 
Gennaro De Libero (G. De Libero), University of Basel; Claire 
Anne Siegrist (C.A. Siegrist), University of Geneva; Nicolas 
Collin (N. Collin), University of Lausanne; Christophe Barnier-
Quer (C. Barnier-Quer), University of Lausanne; Peter Sander 
(P. Sander), University of Zürich. The Gambia: Jayne Sutherland 
(J.S. Sutherland), Medical Research Council. The Netherlands: 
Frank Verreck (F.A.W. Ferreck), Biomedical Primate Research 
Centre (BPRC); Tom Ottenhoff (T.H.M. Ottenhoff), Leiden 
University Medical Center (LUMC); Simone Joosten (S.A. 
Joosten), Leiden University Medical Center (LUMC); Krista 
van Meijgaarden, Leiden University Medical Center (LUMC); 
Mariateresa Coppola, Leiden University Medical Center (LUMC); 
Annemieke Geluk, Leiden University Medical Center (LUMC); 
Nick Drager (N. Drager), Tuberculosis Vaccine Initiative 
(TBVI); Danielle Roordink (D.M. Roordink), Tuberculosis 
Vaccine Initiative (TBVI); Jelle Thole (J. Thole), Tuberculosis 
Vaccine Initiative (TBVI). United Kingdom: Yvonne Perrie 
(Y. Perrie), University of Strathclyde; Marc Baird (M.S. Baird), 
Bangor University; Michael Levin (M. Levin), Imperial College, 
Faculty of Medicine, Department of Medicine & School of Public 
Health; Myrsini Kaforou (M. Kaforou), Imperial College, Faculty 
of Medicine, Department of Medicine & School of Public Health; 
Hazel Dockrell (H.M. Dockrell), London School of Hygiene 
and Tropical Medicine (LSHTM); Steven Smith (S.G. Smith), 
London School of Hygiene and Tropical Medicine (LSHTM); 
Helen Fletcher (H.A. Fletcher), London School of Hygiene and 
Tropical Medicine (LSHTM); Gregory Bancroft (G.J. Bancroft), 
London School of Hygiene and Tropical Medicine (LSHTM); 
Ann Rawkins (A. Williams),  Public Health England; Simon 
Clark (S. Clark), Public Health England;  Sally Sharpe (S. 
Sharpe), Public Health England; Mei Mei Ho (M.M. Ho), The 
Department of Health, UK, acting through PHE and MHRA; 
Helen McShane (H. McShane),   University of Oxford; Iman Satti 
(I. Satti), University of Oxford; Elena Stylianou (E. Stylianou), 
University of Oxford; Rachel Tanner (R. Tanner), University of 
Oxford; Martin Vordermeier (H.M. Vordermeier), Animal and 
Plant Health Agency (APHA); Philip Hogarth (P.J. Hogarth), 
Animal and Plant Health Agency (APHA). United States of 
America: Danilo Casimiro (D. Casimiro), Aeras.
The mentioned investigators have all conducted and/or con-
tributed to the R&D activities of TBVAC2020 project described 
in this manuscript.
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